ImageneOI is the first NSCLC genomic profiling AI tool on the Sectra Amplifier Marketplace.

TEL AVIV, Israel, February 12, 2024 (Newswire.com) - Imagene, a pioneer in AI-based precision oncology, today announced the integration of its groundbreaking AI-based biomarker profiling platform, ImageneOI^TM, with international medical imaging IT company Sectra and their digital pathology solution. Healthcare providers around the world using the Sectra platform can integrate ImageneOI to seamlessly access and use the rapid AI-based NSCLC biomarker profiling within their existing digital pathology workflows.

ImageneOI utilizes artificial intelligence to rapidly profile a broad range of cancer biomarkers from digitized H&E biopsy images alone. The integration with the Sectra digital pathology solution initially focuses on Non-Small Cell Lung Cancer (NSCLC), the deadliest cancer, and is the first and currently the only molecular biomarker profiling tool on the Sectra marketplace.

“The availability of ImageneOI via the Sectra Amplifier Marketplace marks an important step in our mission to make rapid AI-based biomarker profiling widely accessible and integrated within the pathology workflows,” said Dean Bitan, Co-founder and CEO of Imagene. “It empowers healthcare providers with immediate molecular profiling capabilities within the premises of their pathology labs, enabling them to make timely well-informed decisions.”

ImageneOI sets a new paradigm in biomarker profiling, overcoming key barriers and limitations in current methods. It enables faster turnaround times, delivering results within minutes from uploading the biopsy image, and providing crucial molecular information at the pathology lab. It streamlines processes and assists in prioritizing the use of tissue samples and further testing, thereby navigating the diagnosis route in an optimal way. This efficiency is particularly vital in time-sensitive cancers, like NSCLC.

The Sectra Amplifier Marketplace, a hub for cutting-edge pathology and radiology AI applications, will feature ImageneOI, available for research use only, as the first NSCLC molecular biomarker panel in the marketplace. This inclusion ensures wider accessibility of this transformative technology across a vast network of hospitals and laboratories.

About Imagene

Imagene is an emerging leader in AI-based precision oncology, leveraging AI to profile a broad range of cancer biomarkers from digitized biopsy images within minutes. The company empowers physicians with immediate oncology intelligence, facilitating optimal treatment decisions for more cancer patients. Awarded the 2023 Digital Health Award for “Best Use of AI in HealthTech” and the Technology Leadership Best Practices Award by Frost & Sullivan, Imagene's success derives from its cutting-edge technology and multidisciplinary team of experts dedicated to advancing precision oncology and improving cancer patient care.

For more information, please visit imagene-ai.com

Contact Information:
Avital Rabani
VP of Marketing
[email protected]


Original Source: Imagene Increases Accessibility of Rapid AI-Based Biomarker Profiling Through Integration With Sectra

Beyond Traditional Care: How Sensay's AI Companions Are Crafting Personalized Support

SAN FRANCISCO, February 9, 2024 (Newswire.com) - In a world where over 55 million people are living with dementia—a number projected to rise dramatically in the coming decades—Sensay introduces a transformative solution that stands at the forefront of healthcare innovation. As dementia increasingly challenges individuals' memory, cognitive abilities, and emotional well-being, Sensay emerges not merely as a product but as a beacon of hope, blending cutting-edge AI with deep empathy to revolutionize care for those affected.

The Challenge of Dementia Care

Dementia and Alzheimer's disease not only strip individuals of precious memories but often lead to emotional and social isolation, complicating daily tasks and personal care. The burden on caregivers is immense, with geographic and economic factors further limiting access to quality care. Sensay addresses these challenges head-on, providing a solution that transcends traditional care methods.

Sensay's Innovative Support

At the heart of Sensay's platform is the use of advanced AI to create digital replicas of patients, preserving their memories, voices, and personalities, offering users a sense of continuity and connection. Interactive AI companions provide personalized engagement, while cognitive stimulation activities aim to track the progression of symptoms. Sensay also offers invaluable support to caregivers, fostering a community of advice and support.

Sensay's foundation is a deep commitment to preserving the richness of individual histories and memories, utilizing technology to maintain the essence of cherished relationships. The platform's design is intuitive and accessible, ensuring ease of use regardless of technological proficiency. 

With over 20,000 users, Sensay's effectiveness is reflected by early testimonials and research findings, demonstrating significant improvements in users' emotional well-being and cognitive engagement.

Key Features of Sensay

- Digital Replication of Memories: Digitally replicates loved ones' voices, images, and personalities.
- Cognitive Stimulation: Daily reminders and personalized exercises designed to combat the progression of dementia symptoms.
- Support for Caregivers: Provides resources and tools to alleviate caregiver stress and promote effective care strategies.

Sensay's Impact

Sensay is more than a technological innovation; it's a comprehensive solution that enhances the lives of those affected by dementia. By replicating familiar people and memories, Sensay offers comfort and familiarity, addressing the emotional and social challenges of dementia. As the platform learns and adapts, it promises increasingly personalized support, making a tangible difference in the lives of users and caregivers alike.

Dan Thomson, Founder of Sensay, shares his vision: “At the heart of Sensay is a commitment to reimagining dementia care. We believe in the power of technology to preserve the essence of our shared humanity—our memories, voices, and the stories that define us. As we look to the future, our goal is to bridge the gap between technology and empathy, ensuring that every individual with dementia can maintain a connection to their identity and loved ones.”

By harnessing the power of technology, Sensay is committed to improving the quality of life for millions affected by dementia worldwide. 

Contact:
www.sensay.io
[email protected]
@asksensay

Contact Information:
Dan Thomson
Press Office
[email protected]


Original Source: Sensay Introduces Revolutionary AI Dementia Care

The annual award honors Roberts’ special service to the patients and families that are served by the ASTCT community.

CHICAGO, February 9, 2024 (Newswire.com) - The American Society for Transplantation and Cellular Therapy® (ASTCT) will present Robin Roberts, Good Morning America anchor, with its 2024 Public Service Award at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® on Friday, February 23. The annual award recognizes an individual who has advanced the interests of patients or given special service to the patients and families ASTCT serves.

ASTCT is essential in securing the highest industry standards and guidelines for hematopoietic cell transplantation (HCT) and cellular therapy patients to bring the best in comprehensive care across the world. Gene and cell therapy are at the cutting edge of medicine today, and ASTCT serves as a resource organization for physicians, researchers and patients, to ensure that the highest quality of data and information is accessible to all who need it. With an international professional membership of 3,600 physicians, investigators and healthcare professionals from more than 45 countries, ASTCT’s mission is dedicated to improving the application and success of advanced life-saving therapies.

In 2012, Roberts received a life-saving blood stem cell transplant to treat myelodysplastic syndrome (MDS). Over the past 10 years, Roberts has been an advocate for the NMDP Registry. Roberts uses her platform to raise awareness and encourage thousands of people to join the registry. Over 140 of those individuals have gone on to donate life-saving blood stem cells to patients in need.

“Robin Roberts is an inspiration to us all,” said ASTCT president Miguel-Angel Perales, MD. “Faced with a devastating diagnosis, she used her platform to bring awareness to bone stem cell transplant and a voice to the many patients in need of a donor. She continues to be a champion for patients by showcasing their stories to a global audience. Her advocacy efforts save the lives of the patients we treat each day and advance breakthroughs in HCT and cell therapy.” 

70% of patients who need a life-saving bone marrow or cord blood transplant do not have a fully matched donor in their family. ASTCT works in partnership with patient and donor advocate organizations to remove barriers to transplantation and protect donors who choose to save a life. ASTCT endeavors every day to bring visionary tools, guidelines and resources to pioneer and elevate stem and immune cell therapies that will ensure better patient outcomes across many disease categories.

Contact Information:
Jennifer Kasowicz
ASTCT Marketing Director
[email protected]
(312) 673-4970


Original Source: American Society for Transplantation and Cellular Therapy Awards Robin Roberts With the 2024 Public Service Award

BOSTON, February 9, 2024 (Newswire.com) - ProCell® Surgical Inc. has successfully been registered and is certified to be compliant to the requirements of ISO 13485:2016 under the MDSAP scope. Additionally, ProCell® has received CE marked approval for its Sponge Blood Recovery Unit which has been found in conformity with Regulation (EU) 2017/745 for Medical Devices. 

The company’s unique patented design effectively replaces the manual and outdated activity of hand-wringing for surgical sponge-blood recovery with intraoperative autotransfusion (IAT). ProCell® will augment an institution's existing IAT device and put hospitals at the forefront among institutions, providing an exceptional new standard of patient care, which is also more cost-effective.

Blood donorship has decreased significantly over the past several years, especially during the pandemic. With an automated, more efficient blood collection process, ProCell® removes the risk of not using autologous blood. IAT is used routinely in the operating room and has been shown to reduce the requirements for donor blood transfusions during surgery along with their associated risk and supply chain issues.

ProCell® is an important tool in any patient blood management/blood conservation armamentarium and has the potential to help in the overall effort, especially when sponge blood accounts for 30% to 50% of total blood loss during surgery. With ProCell® all efforts should be made to optimize that recovery.

Marc Pelletier (MD, MSc, FRCSC), the Chief of Cardiac Surgery at University Hospitals Cleveland Medical Center, describes his surgery team’s experience with ProCell®, "It has added to our blood conservation approach, and has helped us standardize intraoperative blood salvage … in our most complex cases, it is helpful to our nursing team, helping to facilitate the use of extracting blood from multiple sponges, while minimizing distractions to our scrub nurse.”

Pelletier continues, “ProCell® has become a fixture in cardiac surgery at University Hospitals, and an additional tool in the surgical management of complex cardiac surgeries. Our patients only stand to benefit from this type of innovative surgical product.”

“ProCell® Surgical’s sponge blood recovery system brings the first automated innovation for sponge blood recovery directly to the operating room table,” stated Robert Krensky, MD, President and co-inventor of the device. “It is easy to operate and can be used repeatedly during its single-case use. ProCell® essentially closes the technology gap that existed during this important preliminary phase of IAT.” 

Mike Kehoe, CEO of ProCell®, states, “In my 30-plus years of managing medical device companies, this is the only product that I have been involved with that is not only cost-effective and proprietary but represents a generational paradigm shift in the approach to conservation of blood during surgery. Obtaining the CE mark for marketing our unique sponge blood recovery device throughout Europe broadens ProCell’s® geographic reach to provide safe and cost-effective solutions globally.”

More about ProCell®:
ProCell® is a medical device company dedicated to elevating the standard of care through developing and manufacturing proprietary medical devices. Headquartered in Canton, Massachusetts.

For more information, please contact: [email protected].  

Follow ProCell®:
Website | Twitter | Facebook | LinkedIn

Contact Information:
Lauren Watts
Executive Assistant
[email protected]
6176991598


Original Source: ProCell® Receives CE Marked Approval for Selling Into the European Union

SAN DIEGO, February 8, 2024 (Newswire.com) - Against the backdrop of a concerning surge in respiratory diseases leading to widespread alarm across the United States, CorDx has submitted its application for its CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test for FDA’s review. This cutting-edge multiplex test aims to deliver results in just 10 minutes and establishes a new benchmark for detecting and distinguishing the nucleocapsid protein antigens of COVID-19, influenza A, and influenza B.

The lateral flow immunoassay device is designed for qualitative detection and differentiation, with samples collected directly from nasal swabs of individuals suspected of respiratory viral infection. Designed for use in professional point-of-care (POC) settings as well as for over-the-counter (OTC) use, the test will be performed by either healthcare professionals or by individuals themselves.

CorDx's new multiplex rapid test kit will deliver rapid results in just 10 minutes, proving to be a game-changer in the current healthcare landscape. The rapid test's multiplex capabilities provide an efficient and accurate diagnostic solution, crucial as both influenza and COVID-19 cases continue to rise.

"The introduction of this multiplex rapid test is a critical step forward in our fight against respiratory viral infections. We’ve received a high volume of calls from across the country expressing interest in us developing this type of multiplex rapid test solution, and we will urgently expand our production lines in Georgia and California to meet this surging demand immediately after FDA’s EUA confirmation,” stated Jeff (Aiiso) Yufeng Li, CorDx’s founder and CSO.

Dr. Jack Hou, CorDx Tyfast’s Associate Scientific Director, also shared his insights on the multiplex product. "Its ability to deliver fast and accurate results for both influenza and COVID-19 from a single sample is unparalleled. Based on current clinical results, our multiplex test kits have demonstrated exceptional performance,” stated Dr. Hou. "This will not only improve patient outcomes by facilitating timely and appropriate treatment but also significantly reduce the burden on our healthcare systems."

About CorDx:

CorDx, a global biotechnology organization, is transforming the global diagnostics industry with innovative R&D solutions, a vertically integrated supply chain, and manufacturing footprints in the United States and around the world. CorDx develops, manufactures, and distributes diagnostics and related tools that empower users to monitor and improve their health. Its proprietary diagnostic solutions are recognized by families and medical professionals for being affordable, use-friendly, and precise. To learn more, visit CorDx.com.

Contact Information:
Jessica Wills
Marketing Director
[email protected]
8583331122


Original Source: CorDx is Expected to Launch Groundbreaking 10-Minute Solution for Distinguishing COVID-19 and Flu A/B as Respiratory Cases Surge Across the U.S.

Key Initiatives Include Software Upgrades, Product Portfolio Expansion and New Board of Directors

HAYWARD, Calif., February 8, 2024 (Newswire.com) - Accuryn Medical, a leading innovator in addressing hospital-acquired acute kidney injury (AKI), announces the successful completion of its comprehensive restructuring and a new Board of Directors.

Christopher Dewey, the incoming Chairman of Accuryn Medical, said, “We are pleased to announce approval and confirmation of our reorganization plan. This achievement will allow Accuryn Medical to have a clean balance sheet and ample funding that enables us to continue to serve our customers and nearly 70,000 patients we have treated to date while delivering on our business plan (some key initiatives highlighted below). I would like to personally thank our patients, customers, employees, suppliers, partners, investors, advisors, and others involved in this process for their support and continued confidence in Accuryn Medical.”

Key initiatives include:

Software Upgrades: Accuryn recently launched several upgrades to complement Accuryn’s proprietary Active Drain Line technology. Noteworthy is AKI Detect software which detects oliguric Acute Kidney Injury (AKI) in accordance with KDIGO guidelines and provides clinicians early notification of kidney distress compared to the standard of care, serum creatine.

Product Portfolio Expansion: Accuryn Medical has expanded its product portfolio with the introduction of 10 new foley catheter sizes to meet the growing demand to treat a wider range of patients; all designed to reduce the risks associated with CAUTI.

The New Board of Directors: The new Board will be led by Chris Dewey. Dr. Maurice Ferre, Joe Urban (Accuryn’s chief executive officer who successfully navigated Potrero through the restructuring) and an additional two members will be announced next week.

Accuryn Medical is committed to addressing Acute Kidney Injury (AKI) through real-time renal assessment with the Accuryn Monitoring System, which could enable early intervention of AKI to reduce preventable mortality and morbidity. Headquartered in Hayward, California. For more information, visit www.accuryn.com.

Contact Information:
Myria Crawford
VP Marketing
[email protected]
888.635.7280

Jeff Mack
CFO
[email protected]
888.635.7280


Original Source: Accuryn Medical, Formally Known as Potrero Medical Inc., Announces Successful Completion of Restructuring and Over-Subscribed Equity Offering, and is Now Guided by a New Board

NASHVILLE, Tenn., February 8, 2024 (Newswire.com) - Profound Research, a leading clinical trial site network, today announced key leadership appointments aimed at driving innovation and continuing growth. These appointments include Lora Parahovnik, Ph.D., MBA, as Chief Executive Officer, along with the internal promotions of Marty Anderson to Chief Operations Officer and Christopher Church to Chief Commercial Officer.

Dr. Parahovnik brings extensive experience to her new role. She most recently served as CEO at Accel Research Sites Network where her teams set industry benchmarks for patient-centric clinical research within modern healthcare ecosystems. 

“I am honored to join an organization with a vision deeply rooted in improving patient lives, ensuring access to innovative treatments, and propelling scientific and medical progress,” said Parahovnik. “It is a privilege to lead a team whose mission aligns seamlessly with my own values and aspirations.” 

Marty Anderson, promoted to Chief Operations Officer, has been a pivotal figure in Profound's journey, spearheading operations since the company's inception. Her 30-year experience in the clinical trial industry and dedication to operational excellence position Profound for continued growth in both quality and market presence. 

Christopher Church, promoted to Chief Commercial Officer, brings a wealth of experience in building successful commercial teams and driving business development initiatives within the clinical trial industry. His strategic leadership has been focal in expanding Profound's therapeutic area expansion and driving revenue growth. 

Dr. Jonathan Feldstein, President and co-founder of Profound Research, expressed his enthusiasm for these appointments, saying, "We are thrilled to welcome Lora Parahovnik as our CEO and to announce the well-deserved promotions of Marty Anderson and Christopher Church. Their combined ability and leadership will be instrumental in driving Profound Research forward as an industry leader dedicated to medical innovation and patient access to those treatments.”  

About Profound Research

Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients. 

For inquiries, please contact:

[email protected]

Contact Information:
Aaron Mabry
[email protected]


Original Source: Profound Research Charts Exciting Growth Path With Hire of CEO and Strategic Promotions of Key Leadership Roles